First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold A Multi-Imaging Modality Study

JA Ormiston, PWJC (Patrick) Serruys, Yoshinobu Onuma, Robert Jan van Geuns, B de Bruyne, D Dudek, L Thuesen, PC (Pieter) Smits, B Chevalier, D McClean, J Koolen, S Windecker, R Whitbourn, I Meredith, C Dorange, S Veldhof, KM Hebert, R Rapoza, Hector Garcia Garcia

Research output: Contribution to journalArticleAcademicpeer-review

184 Citations (Scopus)


Background-Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes. Methods and Results-The ABSORB trial is a multicenter single-arm trial assessing the safety and performance of an everolimus-eluting bioresorbable vascular scaffold. Forty-five patients underwent serial invasive imaging, such as quantitative coronary angiography, intravascular ultrasound, and optical coherence tomography at 6 and 24 months of follow-up. From 6 to 24 months, late luminal loss increased from 0.16 +/- 0.18 to 0.27 +/- 0.20 mm on quantitative coronary angiography, with an increase i Conclusions-This serial analysis of the second generation of the everolimus-eluting bioresorbable vascular scaffold confirmed, at medium term, the safety and efficacy of the new device.
Original languageUndefined/Unknown
Pages (from-to)620-632
Number of pages13
JournalCirculation-cardiovascular interventions
Issue number5
Publication statusPublished - 2012

Research programs

  • EMC COEUR-09

Cite this